James Greenwell Appointed Chief Operating Officer of MusclePharm
May 14 2014 - 7:30AM
Marketwired
James Greenwell Appointed Chief Operating Officer of MusclePharm
Board Extends Contract of Chief Executive Officer Brad Pyatt and
Executive Vice President of Brand and Social Media Cory Gregory
through 2018
DENVER, CO--(Marketwired - May 14, 2014) - MusclePharm
Corporation (OTCQB: MSLP), a scientifically driven,
performance-lifestyle sports nutrition company, today announced the
appointment of James J. Greenwell as Chief Operating Officer and
the extension of contracts with MusclePharm Co-Founders, Brad
Pyatt, Chairman and Chief Executive Officer, and Cory Gregory,
Executive Vice President of Brand and Social Media, through
2018.
Concurrent with Greenwell's appointment, he has resigned his
position as an independent member of MusclePharm's Board of
Directors. Richard Estalella, the former Chief Operating
Officer, will continue in his position as President of the
Company.
"James has a very strong operational background, coming from one
of the largest material handling companies in the United States. As
a former MusclePharm board member, he has an excellent
understanding of our strategic growth initiatives, which further
enhances the bench strength of the Company's executive management
team," said Pyatt.
"I am very excited to join the MusclePharm team, as the Company
makes its mark on the nutrition industry," Greenwell said. "I look
forward to helping further the Company's impressive growth and
mission to fuel the engine of sports for all ages and genders."
Following is biographical information on Greenwell:
James J. Greenwell
Greenwell has served as a director on MusclePharm's board since
October 2012 and has more than 25 years of management
experience. He has served as Vice President, Voice Products
for Intelligrated, Chairman and CEO of Datria Systems and Senior
Vice President, Sales and Marketing for DecisionOne. Previously, he
served as a technology executive in a number of private and public
companies. Greenwell earned a B.S. from the College of Business at
Michigan State University and an MBA degree from Saint Mary's
College of California.
About MusclePharm MusclePharm® is a scientifically driven,
performance-lifestyle company that currently develops,
manufactures, markets and distributes branded nutritional
supplements. The company offers a complete range of powders,
capsules, tablets and gels. Its portfolio of recognized brands,
including MusclePharm® Hybrid and Core Series, Arnold
Schwarzenegger Series™ and FitMiss®, are marketed and sold in more
than 110 countries and available in over 35,000 retail outlets
globally. These clinically-proven and scientific nutritional
supplements are developed through a six-stage research process
utilizing the expertise of leading nutritional scientists, doctors
and universities. MusclePharm is the innovator of the sports
nutrition industry. For more information, visit
www.musclepharm.com.
Follow the company at http://www.facebook.com/MusclePharm and
www.Twitter.com/MusclePharm
To sign up to receive MusclePharm news via email, please visit
http://ir.musclepharmcorp.com/email-alerts
Forward-Looking Statements This release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities and Exchange
Act of 1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. Actual results may differ materially from
those set forth in this release due to the risks and uncertainties
inherent in the Company's business. More detailed information about
the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2013,
the Company's Quarter Reports on Form 10-Q and other filings
submitted by the Company to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof
Contacts: Matt Sheldon/Evan Pondel PondelWilkinson Inc. (310)
279-5980 investors@musclepharm.com
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024